ArticleJournal of neuro-oncology2025
Effect of combining targeted therapies or chemotherapy with stereotactic radiosurgery (SRS) on the prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC).
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent studies suggest that stereotactic radiosurgery (SRS) increases penetration of systemic drugs into the CNS, and induces immune response to tumor-specific antigens on the surface of tumor cells. Radiation treatment concomitant with immunotherapies and biological treatments for brain metastases (BM) can enhance the body’s immune system to fight the tumor.
methodsA 10-year retrospective cohort study of 61 patients, 18 years and older, with BM from primary non-small cell lung cancer (NSCLC) tumors was divided into those who received targeted therapy according to tumor cell mutations or immunoexpression, and those who received standard chemotherapy for metastatic NSCLC with BM. All patients received the treatment concomitant with or within 2 months following the SRS procedure. Brain progression-free survival (brain-PFS), overall survival (OS), and Karnofsky performance score (KPS) were compared between the two groups.
resultsSignificant differences favoring targeted therapy were observed in brain-PFS (P = 0.001); Five-year OS was 40% vs. 19%, indicating a non-significant trend toward improved survival (P = 0.06). Within the first 6 months, 50% of the chemotherapy group experienced BM disease progression. In contrast, patients receiving targeted therapies showed brain-PFS below 50% over 12 months with a 5-year survival rate of 40%, compared to 19% in the chemotherapy group. After 12 months, 76% of the target group maintained localized brain tumor control (22/30) versus 29% in chemotherapy (9/31) (P = 0.012). Distal BM control was seen in 13% of the targeted therapy group (3/23), while none in chemotherapy exhibited response or control. No significant differences were found in systemic response or systemic PFS between the groups.
conclusionTargeted therapies together with SRS for BM in patients with primary NSCLC tumors significantly improved response and survival rates. Combining these two modalities produced greater response to treatment for both local and distal metastases, longer survival, and improved overall performance compared to the traditional radiation and chemotherapy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.